To examine whether IL-6 could also be involved in astrocyte-dependent neurotoxicity in ID-PD, we added Tocilizumab to the idiopathic ACM (ID-PD ACM) and treated CTL and L2-PD neurons for 1 week. The gene discussed is IL6; the disease is Parkinson disease.